Reni Benjamin
Stock Analyst at Citizens
(1.40)
# 3,547
Out of 5,182 analysts
165
Total ratings
36.96%
Success rate
-13.24%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Downgrades: Market Perform | n/a | $0.36 | - | 1 | Mar 13, 2026 | |
| IMMX Immix Biopharma | Initiates: Market Outperform | $23 | $9.09 | +153.03% | 1 | Mar 9, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $2.62 | +90.84% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $5.31 | +88.32% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $4.90 | +144.90% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $62.35 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.19 | +962.70% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $4.66 | -78.54% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $93.69 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $6.43 | - | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $12 → $4 | $1.00 | +300.00% | 5 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.32 | +72.41% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.14 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.70 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $9.26 | +7.99% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $3 → $6 | $4.40 | +36.36% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $25.71 | -10.54% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.15 | +58.73% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.82 | +217.46% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.45 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $19.22 | +108.12% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.32 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $11.72 | -31.74% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $43.97 | +36.46% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.81 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $127.51 | +147.04% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $71.73 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $219.22 | +20.88% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.96 | +329.29% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.80 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $3.35 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $33.39 | -64.06% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.03 | - | 1 | Nov 15, 2017 |
Immutep
Mar 13, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.36
Upside: -
Immix Biopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $23
Current: $9.09
Upside: +153.03%
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $2.62
Upside: +90.84%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $5.31
Upside: +88.32%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $4.90
Upside: +144.90%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $62.35
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.19
Upside: +962.70%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $4.66
Upside: -78.54%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $93.69
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.43
Upside: -
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.00
Upside: +300.00%
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.32
Upside: +72.41%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.14
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.70
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $9.26
Upside: +7.99%
Mar 11, 2026
Maintains: Market Outperform
Price Target: $3 → $6
Current: $4.40
Upside: +36.36%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $25.71
Upside: -10.54%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.15
Upside: +58.73%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.82
Upside: +217.46%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.45
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $19.22
Upside: +108.12%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.32
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $11.72
Upside: -31.74%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $43.97
Upside: +36.46%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.81
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $127.51
Upside: +147.04%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $71.73
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $219.22
Upside: +20.88%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.96
Upside: +329.29%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.80
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.35
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $33.39
Upside: -64.06%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.03
Upside: -